Atellica CH Urine Albumin REF: 11537225, in vitro diagnostic Recall
Atellica CH Urine Albumin REF: 11537225, in vitro diagnostic
FDA recall Class II
Ongoing
FDA lists this Class II recall for Atellica CH Urine Albumin REF: 11537225, in vitro diagnostic. Review the affected identifiers, reported reason and manufacturer instructions below.
Recall at a glance
- Recall number
- Z-2890-2026
- Recall classification
- Class II
- Enforcement status
- Ongoing
- Initiation date
- Jul 6, 2026
- FDA report date
- Aug 12, 2026
- Quantity in commerce
- 7018 units
- Distribution
- See key details
- FDA cause
- Under Investigation by firm
What is being recalled?
Atellica CH Urine Albumin REF: 11537225, in vitro diagnostic
Affected model & UDI checker
Search the exact identifiers published for Z-2890-2026.
The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.
Affected products
| Model / catalog number | Product | Lot scope reported | UDI / GTIN |
|---|---|---|---|
| 11537225 | Atellica CH Urine Albumin REF: 11537225, in vitro diagnostic | Check source notice | Not specified |
| Not specified | Atellica CH Urine Albumin REF: 11537225, in vitro diagnostic | Check source notice | 00630414611099 |
FDA code information
All Lots within expiry/UDI: 00630414611099
Why was this product recalled?
Processing of urine albumin assay on the CI analyzers may lead to the following issues: Falsely depressed Atellica CH Urea Nitrogen (UN_c) results; Falsely depressed Atellica CH Enzymatic Hemoglobin A1c (A1c_E) results; Increased rate of reaction cuvette QC failures and Delayed results due to QC failures.
What actions did Siemens Healthcare Diagnostics, Inc. take?
On July 6, 2026, Siemens Healthineers issued a Urgent Medical Device Recall to affected consignees via Fed Ex. Siemens Healthineers ask consignees to take the following actions: 1. Discontinue Atellica CH Urine Albumin (UAlb) testing and transition to the Atellica CH Microalbumin_2 (ALB_2) reagent, SMN 11097610, and Atellica CH Microalbumin_2 Calibrator (ALB_2 CAL), SMN 11099435, as an alternate test solution. 2. Replace all reaction cuvette segments following discontinuation of UAlb testing. Refer to the Atellica Solution Online Help for instructions on replacing reaction cuvette segments. 3. Complete the Field Correction Effectiveness Check Form attached to this letter and return within 30 days. 4.Credit will be issued for unexpired UAlb reagent (SMN 11537225), UAlb calibrator (SMN 11537247), and reaction cuvettes segments, as applicable. 5. Please review this letter with your Medical Director to determine the appropriate course of action, including whether review of any previously generated results is warranted. 6. Please retain this letter with your laboratory records and forward this letter to those who may have received the affected product.
Read the manufacturer action recorded by FDARecall timeline
Recall initiated by firm
FDA notice posted
FDA classification recorded
FDA enforcement report date
Related FDA submissions
No submission number with an exact verified relationship is linked in the retrieved recall notice.
FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.
Source and update history
- FDA recall notice Z-2890-2026
- openFDA enforcement record · Source release Nov 11, 2026 · Retrieved Nov 21, 2026
- openFDA device recall record · Source release Nov 19, 2026 · Retrieved Nov 21, 2026
- FDA enforcement data
First stored snapshot of this source.
- FDA device-recall notice
First stored snapshot of this source.
The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.
Our data sources and methodology